Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Snippets - A Small piece of News or Article

Cilta-Cel’s Prolonged Impact: Deep Respon...

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1021Abstract typeOral CARVYKTI (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed, g...

Dec 13, 2023

Phase 2 ELM-2 Study in Patients with DLBCL
Odronextamab Trial: Striking Response Rates and Enduring Outcomes in High-Risk R/R DLBCL Subgroups

Date of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-c...

Find More
Phase 1/2 BRUIN Study of Pirtobrutinib
Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed/Refractory Follicular Lymphoma Patients

Date of Abstract presentation10th December 2023IndicationsFollicular LymphomaAbstract Number3026Abstract typeOral According to the data presented at the ASH 2023 conference, a cohort of 48 patients was analyzed for efficacy, revealing a 50% overall response rate (ORR) and a 14.6% complete response (CR) rate. Add...

Find More
Phase I/II EPCORE NHL-1 Trial Update
EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Therapy: A Game-Changing Alternative in Focus

Date of Abstract presentation9th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number1655Abstract typePoster Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, which is considered incurable and can be difficult to treat in the R/R setting. EPCORE NHL-1 is a multi-center tria...

Find More

More Views & Analysis

Analysis of the Phase 2 PILOT Study
Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients

Date of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose che...

Find More

Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment

Date of Abstract presentation9th December 2023IndicationsChronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)Abstract Number330Abstract typeOral TRANSCEND CLL 004 is the first pivotal, multicenter study of a CD19-directed CAR T cell therapy for patients with relapsed or refractory chronic lymp...

Find More

Highlight of Liso-cel
Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma

Date of Abstract presentation10th December 2023IndicationsFollicular Lymphoma (FL)Abstract Number602Abstract typeOral In the TRANSCEND FL study, 130 individuals grappling with relapsed or refractory follicular lymphoma (FL) were actively involved and subjected to BREYANZI treatment within the second-line and thi...

Find More

Digital Health Major Transformative Trends and Market Dynamics
Digital Health: Insights Into the Key Transformative Trends & Evolving Market Dynamics

Over the past few years, the digital health market has registered immense growth owing to technological advancements and rising demand from the consumer side for better health outcomes. As per the latest assessment by DelveInsight, owing to several favorable factors, the global digital health market is estimated to...

Find More

Clinical Decision Support Systems Market Trends and Outlook
Evaluating the Impact of Clinical Decision Support Systems (CDSS) on Health Outcomes

Clinical Decision Support Systems (CDSS) is one of the most anticipated health technologies that tend to transform treatment dynamics and the healthcare market outlook. With the ongoing development, the CDSS is expected to hold immense potential to bridge the gap between the available patient data and healthcare ex...

Find More

ASH Annual Meeting, Major Abstracts, Breakthroughs, Updates, and News
ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American S...

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More

The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosid.....

Find More

Toll-like Receptors (TLRs) are a type of pattern recognition receptor (PRR) that recognizes pathogen.....

Find More

Cancer, an immunologic condition that can begin in any organ or tissue of the body is the second lea.....

Find More

Soft-tissue sarcoma (STS) is a rare sarcoma that develops in connective tissues such as the muscles,.....

Find More

Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of.....

Find More